Panbela Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Panbela Therapeutics generated cash of -$25,249,000, which is less than the previous year. Cash used in financing activities reached the amount of $26,142,000 last year. Net change in cash is therefore $1,293,000.
Cash Flow
| 2014 | -11.45K | 124.72K | -8.31K |
|---|---|---|---|
| 2015 | -3.89M | 500K | 2.67K |
| 2016 | -2.39M | 0 | 1.91K |
| 2017 | -3.40M | 0 | 3.10K |
| 2018 | -2.38M | 0 | 3.64M |
| 2019 | -2.73M | 0 | 3.78M |
| 2020 | -3.85M | 0 | 10.44M |
| 2021 | -6.70M | -540K | 10.09M |
| 2022 | -15.27M | -656K | 5.35M |
| 2023 | -25.24M | 400K | 26.14M |
PBLA Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 1.28M | 11.86M | 9.02M | 2.44M | 1.40M | 152K | 438K | 925K | 1.65M | 58.82K |
Operating activities | ||||||||||
Net income | -25.26M | -34.93M | -10.13M | -4.76M | -6.2M | -5.90M | -10.37M | -5.11M | -4.92M | -107.04K |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 0 | 0 | 0 | 114K | 2.06M | 0 | 0 | 28K | 28K | 9.57K |
Stock-based compensation expense | 823K | 1.08M | 1.28M | 1.20M | 1.09M | 0 | 1.73M | 902K | 976K | 0 |
| Deferred income tax benefit | 823K | 1.08M | 1.28M | 1.20M | 1.09M | 0 | 1.73M | 902K | 976K | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 212K | 51K | -2K | -31K | 0 | 0 | 0 | -610K | -3.28K |
Inventories | 0 | -212K | -51K | 2K | 31K | 0 | 0 | 0 | 0 | 76.11K |
Accounts payable | 7.06M | 2.24M | 631K | -747K | 301K | 360K | -319K | 1.15M | 681K | -3.65K |
Cash generated by operating activities | -25.24M | -15.27M | -6.70M | -3.85M | -2.73M | -2.38M | -3.40M | -2.39M | -3.89M | -11.45K |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | 0 | -660K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Acquisitions Net | 0 | 4K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 400K | -656K | -540K | 0 | 0 | 0 | 0 | 0 | 500K | 124.72K |
Financing activities | ||||||||||
Common Stock Issued | 23.05M | 5.34M | 9.05M | 11.08M | 3.16M | 2.32M | 47K | 0 | 1.51M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -1.65M | 0 | 0 | -860K | 624K | -14K | 3.05M | 0 | 0 | -8.31K |
Cash used in financing activities | 26.14M | 5.35M | 10.09M | 10.44M | 3.78M | 3.64M | 3.10K | 1.91K | 2.67K | -8.31K |
Net Change In Cash | 1.29M | -10.58M | 2.84M | 6.57M | 1.04M | 1.25M | -286K | -487K | -729K | 104.95K |
Cash at end of period | 2.57M | 1.28M | 11.86M | 9.02M | 2.44M | 1.40M | 152K | 438K | 925K | 163.77K |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |